Neurology

Neurofilament-light – Update from EAN

 

The European Academy of Neurology (EAN) annual congress included new research on neurofilament-light (NfL), an indicator of neuroaxonal damage and one of the more promising biomarkers in multiple sclerosis and other neurodegenerative conditions. Several recent publications have also presented interesting findings that suggest a role for NfL in MS diagnosis, prognosis and treatment selection. Read More

Update on B cells in MS pathophysiology

 

SPECIAL REPORT

Click here to take the survey

In the past few years, considerable attention has focussed on the role of B cells in the pathophysiology of multiple sclerosis, in large part because of the success of anti-CD20 monoclonal antibodies (e.g. rituximab, ocrelizumab) in reducing clinical and radiological disease activity. A novel agent, ofatumumab, is expected soon and other agents (e.g. ublituximab) are in development. Read More

TOPICS:

SPMS: new data and developments

 

Click here to take the SPMS Management survey

A number of recent studies have provided important insights on the pathophysiology, clinical course and treatment of secondary-progressive multiple sclerosis (SPMS). SPMS is generally characterized as a progressive accumulation of disability after an initial relapsing course; further modifiers are active disease (relapses and/or new MRI lesions) with or without progression, not active with progression and not active and no progression (stable disease) (Lublin et al. Neurology 2014;83:278-286).

Read More

TOPICS:

Sun exposure and MS: effects beyond vitamin D

 

Two Swedish case-control studies have reported that the benefits of sun exposure in MS patients occur largely independently of vitamin D (Hedstrom et al. J Neurol 2020;267:1045-1052). The finding has particular relevance during the current COVID-19 pandemic as patients self-isolate indoors.

Read More

TOPICS: